A Safety and Efficacy Study of CC-122 in Combination With Nivolumab in Subjects With Unresectable Hepatocellular Carcinoma (HCC)
Clinical trial NCT02859324 · COMPLETED
Trial details
- NCT number
- NCT02859324
- Sponsor
- Celgene
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-09-20
- Primary completion
- 2020-03-27
- Enrollment
- 21
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.